IGM-2323 is a CD20xCD3 IgM bispecific T-cell engager that kills low CD20-expressing and rituximab-resistant B-cell lymphomas

被引：0
|
作者：
Li, K. [1 ]
Kotturi, M. F. [2 ]
Manlusoc, M. [3 ]
Yun, R. [1 ]
Hinton, P. R. [1 ]
Logronio, K. [2 ]
Baliga, R. [4 ]
Hernandez, G. [5 ]
Sinclair, A. M. [3 ]
Carroll, S. F. [2 ]
Godfrey, W. R. [6 ]
Keyt, B. A. [7 ]
机构：
[1] IGM Biosci, Antibody Discovery, Mountain View, CA USA
[2] IGM Biosci, Preclin Sci, Mountain View, CA USA
[3] IGM Biosci, Immunooncol, Mountain View, CA USA
[4] IGM Biosci, Discovery Biol, Mountain View, CA USA
[5] IGM Biosci, Clin Biomarkers, Mountain View, CA USA
[6] IGM Biosci, Clin Dev Clin Stats & Regulatory, Mountain View, CA USA
[7] IGM Biosci, Res & Dev, Mountain View, CA USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.134
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
841P
引用
收藏
页码：S778 / S779
页数：2
相关论文
共 50 条
  • [1] High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killing
    Hart, Kevin C.
    Logronio, Kathryn
    Li, Mandy
    Yakkundi, Poonam
    Manlusoc, Marigold
    Li, Keyu
    Hinton, Paul R.
    Ng, Dean
    Leabman, Maya K.
    Hernandez, Genevive
    Manley, Thomas
    Sinclair, Angus M.
    Carroll, Stephen F.
    Keyt, Bruce A.
    Kotturi, Maya F.
    CANCER RESEARCH, 2022, 82 (12)
  • [2] High Avidity IgM-Based CD20xCD3 Bispecific Antibody (IGM-2323) for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release
    Baliga, Ramesh
    Li, Keyu
    Manlusoc, Marigold
    Hinton, Paul
    Ng, Dean
    Tran, Madeline
    Shan, Bing
    Lu, Hai
    Saini, Avneesh
    Rahman, Sachi
    Cao, Yuan
    Saraiya, Chitra
    Peterson, Marvin
    Carroll, Steve
    Chen, Daniel
    Keyt, Bruce
    BLOOD, 2019, 134
  • [3] Lymphoma cell-killing activity and cytokine release by CD20-directed bispecific IgM antibody-based T-cell engager (IGM-2323).
    Keyt, Bruce
    Baliga, Ramesh
    Li, Keyu
    Manlusoc, Marigold
    Hinton, Paul
    Ng, Dean
    Tran, Madeline
    Shan, Bing
    Lu, Hai
    Rahman, Sachi
    Saini, Avneesh
    Cao, Yuan
    Saraiya, Chitra
    Peterson, Marvin
    Godfrey, Wayne R.
    Carroll, Steve
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies
    Hernandez, Genevive H.
    So, John
    Logronio, Kathryn A.
    Kotturi, Maya F.
    Kim, Won Seog
    Armand, Philippe
    Cheah, Chan Y.
    Gopal, Ajay K.
    Flinn, Ian W.
    Gregory, Gareth P.
    Matasar, Matthew J.
    Nastoupil, Loretta J.
    Diefenbach, Catherine S.
    Yoon, Sung-Soo
    Ku, Matthew
    Qazi, Ibrahim
    Leabman, Maya K.
    Sison, Iris
    Keyt, Bruce A.
    Takimoto, Chris H.
    Manley, Thomas J.
    Budde, Elizabeth L.
    BLOOD, 2022, 140 : 6436 - 6438
  • [5] A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies
    Budde, Elizabeth
    Gopal, Ajay K.
    Kim, Won Seog
    Flinn, Ian W.
    Cheah, Chan Yoon Y.
    Nastoupil, Loretta
    Matasar, Matthew J.
    Diefenbach, Catherine S.
    Gregory, Gareth P.
    Qazi, Ibrahim
    Pang, Ching-Fai
    Leabman, Maya
    Hernandez, Genevive
    Sison, Iris
    Keyt, Bruce A.
    Chen, Daniel
    Armand, Philippe
    BLOOD, 2021, 138
  • [6] Tafasitamab in Combination with a CD20xCD3 Bispecific T-Cell Engager Significantly Prolongs Survival in Preclinical Lymphoma Models
    Schaadt, Eveline
    Heitmueller, Christina
    Peters, Solveig
    Ilieva, Kristina
    Blair, Derek
    Huth, Christiane
    Bartel, Dominik
    Zapf, Sandra
    Eberl, Markus
    Mangelberger-Eberl, Doris
    Giles, Frank
    Corvey, Carsten
    BLOOD, 2023, 142
  • [7] Depletion of tissue-resident B cells by a CD20xCD3 IgM bispecific T cell engager in cynomolgus monkeys demonstrates effective tissue penetration and potent target cell killing
    Oyasu, Miho
    Sinclair, Angus M.
    Ghermazien, Haben
    Hernandez, Genevive
    Manley, Thomas
    Leabman, Maya K.
    Carroll, Stephen F.
    Keyt, Bruce A.
    Kotturi, Maya F.
    CANCER RESEARCH, 2023, 83 (07)
  • [8] CD3xCD20 bispecific T-cell redirectors for relapsed or refractory B-cell lymphoma
    Ghobadi, Armin
    Bartlett, Nancy L.
    LANCET, 2021, 398 (10306): : 1109 - 1110
  • [9] Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, Effectively Depletes Low-Expressing CD20+B Cells in Preclinical Models of Autoimmune Disease
    Domingo-Gonzalez, Racquel
    Baribaud, Isabelle
    Tyagi, Shrishti
    Hart, Kevin
    Eberwine, Ryan
    Sinclair, Angus
    Candia, Albert
    Keyt, Bruce
    Elloso, Merle
    Kotturi, Maya
    Harler, Mary Beth
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 3133 - 3134
  • [10] Novel CD38xCD3 bispecific IgM T cell engager, IGM-2644, potently kills multiple myeloma cells though complement and T cell dependent mechanisms
    Li, Keyu
    Yun, Rui
    Chai, Min
    Yakkundi, Poonam
    Rosete, Rodnie
    Li, Gene
    Liu, Liqin
    Li, Mandy
    Santos, Daniel
    Hart, Kevin C.
    Ng, Dean
    Hinton, Paul R.
    Muchhal, Umesh
    Manley, Thomas
    Kotturi, Maya F.
    Carroll, Stephen F.
    Sinclair, Angus M.
    Keyt, Bruce A.
    CANCER RESEARCH, 2023, 83 (07)
12345